Cargando…

An Experimental Pipeline for Initial Characterization of Bacterial Type III Secretion System Inhibitor Mode of Action Using Enteropathogenic Yersinia

Dozens of Gram negative pathogens use one or more type III secretion systems (T3SS) to disarm host defenses or occupy a beneficial niche during infection of a host organism. While the T3SS represents an attractive drug target and dozens of compounds with T3SS inhibitory activity have been identified...

Descripción completa

Detalles Bibliográficos
Autores principales: Morgan, Jessica M., Lam, Hanh N., Delgado, Jocelyn, Luu, Justin, Mohammadi, Sina, Isberg, Ralph R., Wang, Helen, Auerbuch, Victoria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262202/
https://www.ncbi.nlm.nih.gov/pubmed/30524970
http://dx.doi.org/10.3389/fcimb.2018.00404
_version_ 1783375058095308800
author Morgan, Jessica M.
Lam, Hanh N.
Delgado, Jocelyn
Luu, Justin
Mohammadi, Sina
Isberg, Ralph R.
Wang, Helen
Auerbuch, Victoria
author_facet Morgan, Jessica M.
Lam, Hanh N.
Delgado, Jocelyn
Luu, Justin
Mohammadi, Sina
Isberg, Ralph R.
Wang, Helen
Auerbuch, Victoria
author_sort Morgan, Jessica M.
collection PubMed
description Dozens of Gram negative pathogens use one or more type III secretion systems (T3SS) to disarm host defenses or occupy a beneficial niche during infection of a host organism. While the T3SS represents an attractive drug target and dozens of compounds with T3SS inhibitory activity have been identified, few T3SS inhibitors have been validated and mode of action determined. One issue is the lack of standardized orthogonal assays following high throughput screening. Using a training set of commercially available compounds previously shown to possess T3SS inhibitory activity, we demonstrate the utility of an experiment pipeline comprised of six distinct assays to assess the stages of type III secretion impacted: T3SS gene copy number, T3SS gene expression, T3SS basal body and needle assembly, secretion of cargo through the T3SS, and translocation of T3SS effector proteins into host cells. We used enteropathogenic Yersinia as the workhorse T3SS-expressing model organisms for this experimental pipeline, as Yersinia is sensitive to all T3SS inhibitors we tested, including those active against other T3SS-expressing pathogens. We find that this experimental pipeline is capable of rapidly distinguishing between T3SS inhibitors that interrupt the process of type III secretion at different points in T3SS assembly and function. For example, our data suggests that Compound 3, a malic diamide, blocks either activity of the assembled T3SS or alters the structure of the T3SS in a way that blocks T3SS cargo secretion but not antibody recognition of the T3SS needle. In contrast, our data predicts that Compound 4, a haloid-containing sulfonamidobenzamide, disrupts T3SS needle subunit secretion or assembly. Furthermore, we suggest that misregulation of copy number control of the pYV virulence plasmid, which encodes the Yersinia T3SS, should be considered as a possible mode of action for compounds with T3SS inhibitory activity against Yersinia.
format Online
Article
Text
id pubmed-6262202
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-62622022018-12-06 An Experimental Pipeline for Initial Characterization of Bacterial Type III Secretion System Inhibitor Mode of Action Using Enteropathogenic Yersinia Morgan, Jessica M. Lam, Hanh N. Delgado, Jocelyn Luu, Justin Mohammadi, Sina Isberg, Ralph R. Wang, Helen Auerbuch, Victoria Front Cell Infect Microbiol Cellular and Infection Microbiology Dozens of Gram negative pathogens use one or more type III secretion systems (T3SS) to disarm host defenses or occupy a beneficial niche during infection of a host organism. While the T3SS represents an attractive drug target and dozens of compounds with T3SS inhibitory activity have been identified, few T3SS inhibitors have been validated and mode of action determined. One issue is the lack of standardized orthogonal assays following high throughput screening. Using a training set of commercially available compounds previously shown to possess T3SS inhibitory activity, we demonstrate the utility of an experiment pipeline comprised of six distinct assays to assess the stages of type III secretion impacted: T3SS gene copy number, T3SS gene expression, T3SS basal body and needle assembly, secretion of cargo through the T3SS, and translocation of T3SS effector proteins into host cells. We used enteropathogenic Yersinia as the workhorse T3SS-expressing model organisms for this experimental pipeline, as Yersinia is sensitive to all T3SS inhibitors we tested, including those active against other T3SS-expressing pathogens. We find that this experimental pipeline is capable of rapidly distinguishing between T3SS inhibitors that interrupt the process of type III secretion at different points in T3SS assembly and function. For example, our data suggests that Compound 3, a malic diamide, blocks either activity of the assembled T3SS or alters the structure of the T3SS in a way that blocks T3SS cargo secretion but not antibody recognition of the T3SS needle. In contrast, our data predicts that Compound 4, a haloid-containing sulfonamidobenzamide, disrupts T3SS needle subunit secretion or assembly. Furthermore, we suggest that misregulation of copy number control of the pYV virulence plasmid, which encodes the Yersinia T3SS, should be considered as a possible mode of action for compounds with T3SS inhibitory activity against Yersinia. Frontiers Media S.A. 2018-11-22 /pmc/articles/PMC6262202/ /pubmed/30524970 http://dx.doi.org/10.3389/fcimb.2018.00404 Text en Copyright © 2018 Morgan, Lam, Delgado, Luu, Mohammadi, Isberg, Wang and Auerbuch. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cellular and Infection Microbiology
Morgan, Jessica M.
Lam, Hanh N.
Delgado, Jocelyn
Luu, Justin
Mohammadi, Sina
Isberg, Ralph R.
Wang, Helen
Auerbuch, Victoria
An Experimental Pipeline for Initial Characterization of Bacterial Type III Secretion System Inhibitor Mode of Action Using Enteropathogenic Yersinia
title An Experimental Pipeline for Initial Characterization of Bacterial Type III Secretion System Inhibitor Mode of Action Using Enteropathogenic Yersinia
title_full An Experimental Pipeline for Initial Characterization of Bacterial Type III Secretion System Inhibitor Mode of Action Using Enteropathogenic Yersinia
title_fullStr An Experimental Pipeline for Initial Characterization of Bacterial Type III Secretion System Inhibitor Mode of Action Using Enteropathogenic Yersinia
title_full_unstemmed An Experimental Pipeline for Initial Characterization of Bacterial Type III Secretion System Inhibitor Mode of Action Using Enteropathogenic Yersinia
title_short An Experimental Pipeline for Initial Characterization of Bacterial Type III Secretion System Inhibitor Mode of Action Using Enteropathogenic Yersinia
title_sort experimental pipeline for initial characterization of bacterial type iii secretion system inhibitor mode of action using enteropathogenic yersinia
topic Cellular and Infection Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262202/
https://www.ncbi.nlm.nih.gov/pubmed/30524970
http://dx.doi.org/10.3389/fcimb.2018.00404
work_keys_str_mv AT morganjessicam anexperimentalpipelineforinitialcharacterizationofbacterialtypeiiisecretionsysteminhibitormodeofactionusingenteropathogenicyersinia
AT lamhanhn anexperimentalpipelineforinitialcharacterizationofbacterialtypeiiisecretionsysteminhibitormodeofactionusingenteropathogenicyersinia
AT delgadojocelyn anexperimentalpipelineforinitialcharacterizationofbacterialtypeiiisecretionsysteminhibitormodeofactionusingenteropathogenicyersinia
AT luujustin anexperimentalpipelineforinitialcharacterizationofbacterialtypeiiisecretionsysteminhibitormodeofactionusingenteropathogenicyersinia
AT mohammadisina anexperimentalpipelineforinitialcharacterizationofbacterialtypeiiisecretionsysteminhibitormodeofactionusingenteropathogenicyersinia
AT isbergralphr anexperimentalpipelineforinitialcharacterizationofbacterialtypeiiisecretionsysteminhibitormodeofactionusingenteropathogenicyersinia
AT wanghelen anexperimentalpipelineforinitialcharacterizationofbacterialtypeiiisecretionsysteminhibitormodeofactionusingenteropathogenicyersinia
AT auerbuchvictoria anexperimentalpipelineforinitialcharacterizationofbacterialtypeiiisecretionsysteminhibitormodeofactionusingenteropathogenicyersinia
AT morganjessicam experimentalpipelineforinitialcharacterizationofbacterialtypeiiisecretionsysteminhibitormodeofactionusingenteropathogenicyersinia
AT lamhanhn experimentalpipelineforinitialcharacterizationofbacterialtypeiiisecretionsysteminhibitormodeofactionusingenteropathogenicyersinia
AT delgadojocelyn experimentalpipelineforinitialcharacterizationofbacterialtypeiiisecretionsysteminhibitormodeofactionusingenteropathogenicyersinia
AT luujustin experimentalpipelineforinitialcharacterizationofbacterialtypeiiisecretionsysteminhibitormodeofactionusingenteropathogenicyersinia
AT mohammadisina experimentalpipelineforinitialcharacterizationofbacterialtypeiiisecretionsysteminhibitormodeofactionusingenteropathogenicyersinia
AT isbergralphr experimentalpipelineforinitialcharacterizationofbacterialtypeiiisecretionsysteminhibitormodeofactionusingenteropathogenicyersinia
AT wanghelen experimentalpipelineforinitialcharacterizationofbacterialtypeiiisecretionsysteminhibitormodeofactionusingenteropathogenicyersinia
AT auerbuchvictoria experimentalpipelineforinitialcharacterizationofbacterialtypeiiisecretionsysteminhibitormodeofactionusingenteropathogenicyersinia